Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer

David G Armstrong, Mark A Swerdlow, Alexandria A Armstrong, Michael S Conte, William V Padula, Sicco A Bus, David G Armstrong, Mark A Swerdlow, Alexandria A Armstrong, Michael S Conte, William V Padula, Sicco A Bus

Abstract

Background: In 2007, we reported a summary of data comparing diabetic foot complications to cancer. The purpose of this brief report was to refresh this with the best available data as they currently exist. Since that time, more reports have emerged both on cancer mortality and mortality associated with diabetic foot ulcer (DFU), Charcot arthropathy, and diabetes-associated lower extremity amputation.

Methods: We collected data reporting 5-year mortality from studies published following 2007 and calculated a pooled mean. We evaluated data from DFU, Charcot arthropathy and lower extremity amputation. We dichotomized high and low amputation as proximal and distal to the ankle, respectively. This was compared with cancer mortality as reported by the American Cancer Society and the National Cancer Institute.

Results: Five year mortality for Charcot, DFU, minor and major amputations were 29.0, 30.5, 46.2 and 56.6%, respectively. This is compared to 9.0% for breast cancer and 80.0% for lung cancer. 5 year pooled mortality for all reported cancer was 31.0%. Direct costs of care for diabetes in general was $237 billion in 2017. This is compared to $80 billion for cancer in 2015. As up to one-third of the direct costs of care for diabetes may be attributed to the lower extremity, these are also readily comparable.

Conclusion: Diabetic lower extremity complications remain enormously burdensome. Most notably, DFU and LEA appear to be more than just a marker of poor health. They are independent risk factors associated with premature death. While advances continue to improve outcomes of care for people with DFU and amputation, efforts should be directed at primary prevention as well as those for patients in diabetic foot ulcer remission to maximize ulcer-free, hospital-free and activity-rich days.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Five Year Mortality of Diabetic Foot Complications and Cancer. Diabetic foot complications compared to cancer. DFU = diabetic foot ulcers [11] = 30.5%. Charcot = Charcot neuroarthropathy of the foot [14]. All Cancer = pooled 5 year survival of all cancers [11]. CLTI = chronic limb threatening ischemia [28, 29]. Major Amputation = above foot amputation [–22, 26, 27]. Minor Amputation = foot level amputation [17, 27]

References

    1. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367–2375.
    1. Infection guideline - IWGDF Guidelines. IWGDF Guidelines. . .
    1. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18–25.
    1. IDF Diabetes Atlas 9th edition 2019. . .
    1. Wukich DK, Raspovic KM, Suder NC. Patients with diabetic foot disease fear major lower-extremity amputation more than death. Foot Ankle Spec. 2018;11(1):17–21.
    1. Huang Z-H, Li S-Q, Kou Y, Huang L, Yu T, Hu A. Risk factors for the recurrence of diabetic foot ulcers among diabetic patients: a meta-analysis. . 2019. 10.1111/iwj.13200.
    1. Lazzarini PA, Pacella RE, Armstrong DG, van Netten JJ. Diabetes-related lower-extremity complications are a leading cause of the global burden of disability. . 2018. 10.1111/dme.13680.
    1. Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global Disability Burdens of Diabetes-Related Lower-Extremity Complications in 1990 and 2016. Diabetes Care. 2020. 10.2337/dc19-1614.
    1. Armstrong DG, Kanda VA, Lavery LA, Marston W, Mills JL, Sr, Boulton AJM. Mind the gap: disparity between research funding and costs of care for diabetic foot ulcers. Diabetes Care. 2013;36(7):1815–1817.
    1. Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J. 2007;4(4):286–287.
    1. Cancer Facts & Figures 2019. .
    1. Jeyaraman K, Berhane T, Hamilton M, Chandra AP, Falhammar H. Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. BMC Endocr Disord. 2019;19(1):1.
    1. Amadou C, Carlier A, Amouyal C, et al. Five-year mortality in patients with diabetic foot ulcer during 2009–2010 was lower than expected. . 2019. 10.1016/j.diabet.2019.04.010.
    1. Winkley K, Sallis H, Kariyawasam D, et al. Five-year follow-up of a cohort of people with their first diabetic foot ulcer: the persistent effect of depression on mortality. Diabetologia. 2012;55(2):303–310.
    1. Sohn M-W, Lee TA, Stuck RM, Frykberg RG, Budiman-Mak E. Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care. 2009;32(5):816–821.
    1. Gazis A, Pound N, Macfarlane R, Treece K, Game F, Jeffcoate W. Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot) Diabet Med. 2004;21(11):1243–1246.
    1. Armstrong DG, Peters EJG. Charcot’s arthropathy of the foot. J Am Podiatr Med Assoc. 2002;92(7):390–394.
    1. Wilbek TE, Jansen RB. Jørgensen B, Svendsen OL. The diabetic foot in a multidisciplinary team setting. Number of amputations below ankle level and mortality. Exp Clin Endocrinol Diabetes. 2016;124(9):535–540.
    1. Uzzaman MM, Jukaku S, Kambal A, Hussain ST. Assessing the long-term outcomes of minor lower limb amputations: a 5-year study. Angiology. 2011;62:365–371.
    1. McEwen LN, Ylitalo KR, Munson M, Herman WH, Wrobel JS. Foot complications and mortality: results from translating research into action for diabetes (TRIAD) J Am Podiatr Med Assoc. 2016;106(1):7–14.
    1. Huang Y-Y, Lin C-W, Yang H-M, Hung S-Y, Chen I-W. Survival and associated risk factors in patients with diabetes and amputations caused by infectious foot gangrene. J Foot Ankle Res. 2018;11:1.
    1. Morbach S, Furchert H, Gröblinghoff U, et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012;35(10):2021–2027.
    1. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26:491–494.
    1. Izumi Y, Satterfield K, Lee S, Harkless LB, Lavery LA. Mortality of first-time amputees in diabetics: a 10-year observation. Diabetes Res Clin Pract. 2009;83(1):126–131.
    1. Lavery LA, Hunt NA, Ndip A, Lavery DC, Van Houtum W, Boulton AJM. Impact of chronic kidney disease on survival after amputation in individuals with diabetes. Diabetes Care. 2010;33(11):2365–2369.
    1. Kelly PJ, Clarke PM, Hayes AJ, et al. Predicting mortality in people with type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data. Diabet Med. 2014;31(8):954–962.
    1. Kim YK, Lee HS, Ryu JJ, In Lee H, Seo SG. Sarcopenia increases the risk for mortality in patients who undergo amputation for diabetic foot. J Foot Ankle Res. 2018;11(1):32.
    1. Duff S, Mafilios MS, Bhounsule P, Hasegawa JT. The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019;15:187–208.
    1. Spreen MI, Gremmels H, Teraa M, et al. Diabetes is associated with decreased limb survival in patients with critical limb ischemia: pooled data from two randomized controlled trials. Diabetes Care. 2016;39(11):2058–2064.
    1. Chammas NK, Hill RLR, Edmonds ME. Increased mortality in diabetic foot ulcer patients: the significance of ulcer type. J Diabetes Res. 2016;2016:2879809.
    1. Martins-Mendes D, Monteiro-Soares M, Boyko EJ, et al. The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk. J Diabetes Complications. 2014;28(5):632–638.
    1. Armstrong DG, Mills JL. Toward a change in syntax in diabetic foot care: prevention equals remission. J Am Podiatr Med Assoc. 2013;103(2):161–162.
    1. Khan T, Armstrong DG. Ulcer-free, hospital-free and activity-rich days: three key metrics for the diabetic foot in remission. J Wound Care. 2018;27(Sup4):S3–S4.
    1. AJM B, Armstrong DG, Kirsner RS, et al. Diagnosis and Management of Diabetic Foot Complications. Arlington (VA): American Diabetes Association; 2019.
    1. The Cost of Diabetes | ADA. . .
    1. Driver VR, Fabbi M, Lavery LA, Gibbons G. The costs of diabetic foot: the economic case for the limb salvage team. J Vasc Surg. 2010;52(3 Suppl):17S–22S.
    1. Economic Impact of Cancer. . .
    1. NCI Budget and Appropriations. National Cancer Institute. . .
    1. Najafi B, B Chalifoux C, Everett JB, Razjouyan J, A Brooks E, G Armstrong D. Cost effectiveness of smart insoles in preventing ulcer recurrence for people in diabetic foot remission. Wound Care Manage. 2018;1(1). 10.15761/WCM.1000102.
    1. Raviglione A, Reif R, Macagno M, Vigano D, Schram J, Armstrong D. Real-time smart textile-based system to monitor pressure offloading of diabetic foot ulcers. J Diabetes Sci Technol. 2017;11(5):894–898.
    1. Frykberg RG, Gordon IL, Reyzelman AM, et al. Feasibility and efficacy of a smart mat Technology to predict development of diabetic plantar ulcers. Diabetes Care. 2017;40(7):973–980.
    1. Weinkauf C, Mazhar A, Vaishnav K, Hamadani AA, Cuccia DJ, Armstrong DG. Near-instant noninvasive optical imaging of tissue perfusion for vascular assessment. J Vasc Surg. 2019;69(2):555–562.
    1. Cavanagh P, Attinger C, Abbas Z, Bal A, Rojas N, Xu Z-R. Cost of treating diabetic foot ulcers in five different countries. Diabetes Metab Res Rev. 2012;28(Suppl 1):107–111.
    1. Armstrong DG. Subscription prescription: remote patient monitoring using smart shoes, socks and insoles. J Wound Care. 2019;28(Sup9):S3.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir